Product pipeline includes EVOMELA® (melphalan) for injection, MARQIBO® (vinCRIStine sulfate LIPOSOME injection), ZEVALIN® (ibritumomab tiuxetan) for the greater China market, ENMD-2076 currently in Phase 2 trials, as well as entecavir and the other U.S. ANDA products.
CASI is a U.S. based pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, U.S., and throughout the world. We are a NASDAQ-listed company, with offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China through which substantially all of our operations are conducted.
Our mission is to become an integrated pharmaceutical company with significant market share in China, while establishing partnerships for global development and commercialization. Part of our strategy is to leverage our expertise and resources in China and the U.S. to bring high-quality pharmaceuticals and innovative oncology products to patients and to develop them faster and more cost-effectively using our dual China-U.S. development approach.
This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.
EVOMELA® (melphalan) for Injection, MARQIBO® (vinCRIStine sulfate LIPOSOME injection), ZEVALIN® (ibritumomab tiuxetan) and SPECTRUM PHARMACEUTICALS, INC. ® are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliates. The SPECTRUM PHARMACEUTICALS logos are trademarks owned by Spectrum Pharmaceuticals, Inc.